[1] YU YC, MAO YM, CHEN CW, et al.DILI study group, Chinese socity of hepatology. Csh guideline for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11(3): 221-241. [2] WANG JB, ZHU Y, BAI ZF, et al.Guidelines for the diagnosis and management of herb-induced liver injury[J]. Chin J Integr Med, 2018, 24(9): 696-706. [3] YU YC, FAN Y, CHEN CW.Research status and prospect of liver injury related to herbal and dietary supplements[J]. Chin Heptol(肝脏), 2017, 22(4): 296-300. [4] HOOFNAGLE JH, SERRANO J, KNOBEN JE, et al.LiverTox: a website on drug-induced liver injury[J]. Hepatology, 2013, 57(3): 873-874. [5] MAO YM.HepaTox: a professional network platform to promote clinical and translational research of drug-induced liver injury in China[J]. Chin Heptol(肝脏), 2014, 19(8): 575-576. [6] DANAN G, BENICHOU C.Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries[J]. J Clin Epidemiol, 1993, 46(11): 1323-1330. [7] DANAN G, TESCHKE R.RUCAM in drug and herb induced liver injury: the update[J]. Int J Mol Sci, 2015, 17(1): 14. [8] HAYASHI PH, LUCENA MI, FONTANA RJ, et al.A revised electronic version of RUCAM for the diagnosis of DILI[J]. Hepatology, 2022, 76(1): 18-31. [9] HUANG DL, LI CP, WANG JB, et al.Correlational verification of drug-induced liver injury with HLA-B*3501 allele due to polygonum mutiflorum[J]. Chin J Hepatol(中华肝脏病杂志), 2021, 29(11): 1106-1108. [10] ZHAO WW, SHAN W, ZHANG SW, et al.Clinical analysis of 44 cases of liver injury induced by Tripterygium wilfordii[J]. Chin J Drug Abuse Prevention and Treatment(中国药物滥用防治杂志), 2018, 24(5): 268-271. [11] PENG MM, GE WH, ZHUGE YZ.Clinical analysis on Gynura segetum induced hepatic veno-occlusive disease[J]. Chin J Clin Pharmacol, 2018, 34(8): 938-941. [12] WANG L, WANG Y, WEE A, et al.Clinicopathological features of Bu Gu Zhi-induced liver injury, a long-term follow-up cohort study[J]. Liver Int, 2020, 40(3): 571-580. [13] SHEN H, ZHANG ZY.Natural Drugs and Drug-induced Liver Injury(天然药物与药物性肝损伤)[M]. Nanjing: Southeast University Press, 2020: 201-240. [14] WANG XL, GOU XJ, CHEN L, et al.Metabolomics of Gynura segetum-induced hepatotoxicity in rats[J]. Chin Traditional Patent Medicine, 2019, 41(8): 1826-1834. [15] LI DD, TANG XL, LONG L, et al.Research of hepatotoxicity mechanism of crude Polygonum Multiflorum and Radix Polygonum Multiflorum Preparata based on high-content screening techniques. Chin J Pharmacol Toxicol(中国药理学与毒理学杂志), 2017, 31(6): 626-635. [16] WANG XJ, CHEN CW, FU QC.Drug-induced liver injury related with zhixue capsules: an analysis of 30 gregarious patients[J]. Chin Hepatol(肝脏), 2009, 14(4): 287-290. [17] YU YC, CHEN CW.Pathogenesis of drug-induced liver injury:current understanding and future needs[J]. J Clin Hepatol, 37(11): 2515-2524. [18] European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury[J]. J Hepatol, 2019, 70: 1222-1261. [19] CHALASANI NP, MADDUR H, RUSSO MW, et al.ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. [20] YU YC, FAN Y, CHEN CW.Rechallenge test of drug induced liver injury: Can it be intentional? How to operate? How to judge?[J]. Chin Hepatol(肝脏), 2017, 22(12): 1073-1076. [21] General Office of the National Health Commission, State Administration of Traditional Chinese Medicine Comprehensive Department. Diagnosis and Treatment Protocol for COVID-19 (Trial version 10)[EB/OL]. General Office of the National Health Commission, State Administration of Traditional Chinese Medicine Comprehensive Department. (2023-01-05)[2023-01-16]. http://www.nhc.gov.cn//xcs/zhengcwj/202301/8e6e038fe3ef4b5c9629e0293dd3dd19.shtml. [22] LEISE MD, POTERUCHA JJ, TALWALKAR JA.Drug-induced liver injury[J]. Mayo Clin Proc, 2014, 89(1): 95-106. [23] MA J, XIA Q, FU PP, et al.Pyrrole-protein adducts-a biomarker of pyrrolizidine alkaloid-induced hepatotoxicity[J]. J Food Drug Anal, 2018, 26(3): 965-972. [24] WANG LL, SUN J.Progress in diagnosis and treatment of hepatic sinus obstruction syndrome caused by pyrrole alkaloids[J]. Int J Dig Dis(国际消化病杂志), 2020, 40(2): 96-99. [25] YU YC, HE CL, HOU JL.Biomarkers in drug-induced liver injuries[J]. J Pract Hepatol(实用肝脏病杂志), 2014, 17(6): 564-568. [26] Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines[J]. Hepatol Int, 2021, 15(2): 258-282. [27] ZHUGE Y, LIU Y, XIE W, et al.Chinese society of gastroenterology committee of hepatobiliary disease. expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol(中华消化杂志), 2019, 34(4): 634-642. [28] HU XQ.Discussion on pathological scoring system of drug-induced liver injury[J]. Chin J Hepatol(中华肝脏病杂志), 2012, 20(3): 176-177. [29] HU XQ.Restudy on pathological scoring system of drug-induced liver injury[J]. Chin Hepatol(肝脏), 2014, 19(8): 577-579. [30] LUO Q, ZHU HR, GU HT, et al.Liver histopathological features of patients with drug-induced liver injury due to chinese herbal medicine and western medicine: a comparative analysis of 50 cases[J]. J Clin Hepatol(临床肝胆病杂志), 2020, 36(3): 596-601. [31] JIANG ZL, LI PING, WANG JL, et al.Relationship between liver tissue iron deposition and serum biochemistry and pathology in 106 patients wiht drug-induced liver injury[J]. Chin J Dig(中华消化杂志), 2016, 36(8): 543-547. [32] YANG RY, ZHAO XY.Significance of liver histopathological examination in diagnosis and treatment of drug-induced liver injury[J]. J Chin Hepatol(临床肝胆病杂志), 2018, 34(6): 1172-1175. [33] SOARES PF, FERNANDES MTCF, SOUZA ADS, et al.Causality imputation between herbal products and HILI: an algorithm evaluation in a systematic review[J]. Ann Hepatol, 2021, 25: 100539. [34] DANAN G, TESCHKE R.Drug-induced liver injury: why is the roussel uclaf causality assessment method (RUCAM) still used 25 years after its launch?[J]. Drug Saf, 2018, 41(8): 735-743. [35] LEWIS JH.Digitizing DILI: Who can? RUCAM? RECAM?[J]. Hepatology, 2022, 76(1): 3-5. [36] DANAN G, TESCHKE R.Letter to the editor: electronic RUCAM: major pitfalls call for caution and proper validation[J]. Hepatology, 2022, 76(1): E27. [37] BESSONE F, ROBLES-DIAZ M, HERNANDEZ N, et al.Assessment of serious acute and chronic idiosyncratic drug-induced liver injury in clinical practice[J]. Semin Liver Dis, 2019, 39(3): 381-394. [38] HOU FQ, ZENG Z, WANG GQ.Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes[J]. Cell Biochem Biophys, 2012, 64(2): 77-83. [39] MARTINEZ MA, VUPPALANCHI R, FONTANA RJ, et al.Clinical and histologic features of azithromycin-induced liver injury[J]. Clin Gastroenterol Hepatol, 2015, 13(2): 369-376. [40] LIN NH, YANG HW, SU YJ, et al.Herb induced liver injury after using herbal medicine: a systemic review and case-control study[J]. Medicine (Baltimore), 2019, 98(13): e14992. [41] ZHU Q, ZHANG Y, XUAN J, et al.HLA-A*02:01 allele is associated with transhinone-induced cutancous adverse drug reactions[J]. Pharmacogenomics, 2019, 20(3): 408-414. [42] ROCKEY DC, SEEFF LB, ROCHON J, et al.Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the roussel-uclaf causality assessment method[J]. Hepatology, 2010, 51(6): 2117-2126. |